



DRUG PRIOR AUTHORIZATION COMMITTEE AGENDA

Date:
June 16, 2022

Time:
10:00am – 3:00pm (CST)

Location:
Howerton State Office Building
Conference Room 202
Jefferson City, MO 65109

Additional Meeting Details

The June 16th DPAC meeting will have both in-person and virtual attendance options. Due to strict capacity limits, public attendance will be based on a first come/first serve sign-up, with a limit of

1 individual per organization.

Those unable to join in-person may listen in/provide public comment via Webex. Individuals wishing to attend in-person must contact **Carmen Burton** at Carmen.M.Burton@dss.mo.gov or call (573) 751-6961.

Join Webex Meeting

Meeting number (access code): 2459 115 4820
Meeting password: 2mJnk8gqVz6

Join from a Video System/Application
Dial [24591154820@stateofmo.webex.com](tel:24591154820)
Or dial 173.243.2.68 and enter the meeting number

Join from a Mobile Device (attendees only)
[1-650-479-3207](tel:1-650-479-3207) Call-in toll number (US/Canada)

*** Click HERE for Meeting Documents ***

Opening Statements/Updates

10:00 – 10:05	Welcome, Announcements and Introductions	Chairperson
10:05 – 10:15	Minutes Review	Discussion/Approval
10:15 – 10:25	Pharmacy Program/Budget Update	Elizabeth Short
10:25 – 10:35	Review of Prior Authorization Meeting and Public Hearing	Josh Moore

Old Business

10:35 – 10:45	Implementation Schedule – Criteria for Previously Approved Clinical Edits, Step Therapies and PA's	Josh Moore
---------------	--	------------

New Business

10:45 – 11:00	Proposed Actions - New Drug/Product Review (See Website and Attached Summary) <ul style="list-style-type: none">i. Open Accessii. Clinical Edit/Step Therapyiii. PDL Agentsiv. Prior Authorization	Olivia Rush
---------------	---	-------------

Clinical and Fiscal Edit Review

11:00 – 1:45	<u>Existing Criteria</u> <ul style="list-style-type: none">i. Ampyraii. Botulinum Toxiniii. Crysvita	Josh Moore
--------------	--	------------

- iv. Duchenne Muscular Dystrophy (DMD)
- v. Emsam
- vi. Gamifant
- vii. Immunoglobulin
- viii. Koselugo
- ix. Luxturna
- x. Narcolepsy Inhibitors
- xi. Neuromyelitis Optica Spectrum Disorder (NMOSD)
- xii. Nuedexta
- xiii. Oxandrin
- xiv. Palforzia
- xv. Palynziq
- xvi. Ranexa
- xvii. Reblozyl
- xviii. Selective Serotonin Reuptake Inhibitors (SSRI)
- xix. Synagis
- xx. Tepezza
- xxi. Tolvaptan
- xxii. Transthyretin-Mediated Amyloidosis (ATTR)
- xxiii. Xcopri
- xxiv. Zometa

New Criteria or Revision of Existing Criteria

- i. Besremi
- ii. CAR-T Cell Therapy
- iii. Enjaymo
- iv. Enzyme Deficiency, Select Agents
- v. Iron, Injectable
- vi. Lambert-Eaton Myasthenic Syndrome (LEMS)
- vii. Manufacturers Requiring Prior Authorization
- viii. Psychotropic Medications Polypharmacy
- ix. Parathyroid Hormone (PTH) and Bone Resorption Suppression Related Agents
- x. Serotonin and Norepinephrine Reuptake Inhibitors (SNRI)
- xi. Targeted Immune Modulators, Small Molecule Janus Kinase (JAK) Inhibitors
- xii. Vyvgart

Break

1:45 – 2:00 Lunch

Program Utilization Information – Conduent Update

2:00 – 2:30 Reports Jennifer Colozza

- i. Call Center Statistics
- ii. New Drug Statistics
- iii. “Top 25” Drugs by Cost/Claims

Other Business/Closing Comments

2:30 – 2:50 Other Business

*Informal comments will be accepted from members of the audience at various points in the agenda.
Times noted are approximate, agenda may move more quickly.*

Next Meeting: September 15, 2022

Meeting location and attendance options subject to change

MO HealthNet
615 Howerton Ct
2nd Floor, Conference Room 202
Jefferson City, MO 65109
Public attendance may be limited

Webex

Motion to Close: *I move that this meeting be closed, and that all records and votes pertaining to and/or resulting from this closed meeting be closed, under Section 610.021 Subsection (14),(5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees.*